| Angioedemas, Hereditary
Cinryze vs Haegarda
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Cinryze vs Haegarda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHaegarda has a higher rate of injection site reactions vs Cinryze based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Haegarda but not Cinryze, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cinryze
Haegarda
At A Glance
IV infusion
Every 3-4 days
C1 esterase inhibitor (serpin)
SC injection
Twice weekly
C1-esterase inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary (adults and adolescents 12 years and above) 1,000 IU IV every 3 or 4 days at 1 mL/min (10 min); for inadequate responders, doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered.
Angioedemas, Hereditary (pediatric patients 6-11 years) 500 IU IV every 3 or 4 days at 1 mL/min (5 min); dose may be adjusted up to 1,000 IU every 3 or 4 days based on individual response.
Angioedemas, Hereditary 60 IU/kg by subcutaneous injection twice weekly (every 3 or 4 days); self- or caregiver-administered after reconstitution.
Contraindications
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to CINRYZE or any of its excipients
- Life-threatening hypersensitivity reactions, including anaphylaxis, to C1-INH preparations or any excipient
Adverse Reactions
Most common (>=5%) Headache, nausea, rash, vomiting, fever
Serious Cerebrovascular accident
Postmarketing Local infusion site reactions (inflammation or hematoma at infusion site), hypersensitivity
Most common (>4%) injection site reactions, hypersensitivity, nasopharyngitis, dizziness
Pharmacology
C1 esterase inhibitor (serpin) that regulates complement and intrinsic coagulation (contact system) pathway activation; suppresses contact system activation by inactivating plasma kallikrein and factor XIIa, modulating vascular permeability by preventing bradykinin generation.
C1-esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that inactivates key proteases in the complement, fibrinolytic, and coagulation systems -- including C1r, C1s, factor XIIa, and plasma kallikrein -- thereby preventing bradykinin generation and reducing vascular permeability; HAEGARDA replaces the missing or malfunctioning C1-INH protein in HAE patients.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cinryze
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Haegarda
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Cinryze
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Haegarda
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Cinryze
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Haegarda
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CinryzeView full Cinryze profile
HaegardaView full Haegarda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.